Transforming and unlocking degrader drug discovery, NEOsphere Biotechnologies is turning a traditionally slow process into a systematic, scalable approach for its partners. #AdFeature with NEOsphere Biotechnologies GmbH https://lnkd.in/dHg2Td25
Biopharma Dealmakers
Biotechnology Research
Nurturing biopharma partnerships. A Nature Research publication.
About us
Biopharma Dealmakers – a Nature Research publication – showcases active partnering companies and their opportunities across the biopharma industry.
- Website
-
https://www.nature.com/biopharmdeal
External link for Biopharma Dealmakers
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- London
- Founded
- 2007
Updates
-
Lantheus aims to transform Alzheimer's disease diagnosis by advancing high-quality imaging agents for beta-amyloid and tau, enabling earlier, more-precise and more-accessible detection. https://lnkd.in/erfNyE82
-
Discover how NEOsphere’s intuitive software neoVERSE streamlines the analysis of large-scale proteomics data to drive drug discovery decisions. #AdFeature with NEOsphere Biotechnologies GmbH https://lnkd.in/dHg2Td25
-
Explore how Lantheus is expanding its radiodiagnostic portfolio into neurology, with novel PET imaging agents targeting tau and beta-amyloid. The move reflects growing demand for precision tools in Alzheimer’s care. https://lnkd.in/eTG9zv9g
-
Thanks Andy, dealmaking activity for RNA-based drugs is nicely summarised here in our latest issue. https://lnkd.in/eRawjJXa
A look (https://lnkd.in/evkwFHxr) at recent deal activity in RNA-targeted medicines from the past year or so I did for Biopharma Dealmakers. Interesting uptick in delivery deals and RNA manufacturing know-how. Thanks to John Maraganore and Myles Minter for providing their insights
-
Backed by several studies, Hua Medicine’s progress on glucokinase activators is bringing new hope to type 2 diabetes patients. Could you develop the programs further? #AdFeature with Hua Medicine https://lnkd.in/dcPEVgRj
-
Together Harbour BioMed and Nona Biosciences provide a dual-pillar business model that leverages antibody discovery services and technology platforms to enable partners to meet development goals. #AdFeature with Harbour BioMed https://lnkd.in/dE6xrPef
-
Combining advanced engineering with high-precision biosynthesis, Nutcracker Therapeutics has created an RNA platform that significantly reduces costs and cycle times. #AdFeature with Nutcracker Therapeutics https://lnkd.in/diVH5gjY
-
Transforming targeted intracellular delivery, antibody-drug conjugates and cytotoxic payloads can reach their target site with the aid of the Accum molecule. #AdFeature with Defence Therapeutics https://lnkd.in/dp6ejfp4
-
Discover unique antibodies that activate only in the presence of disease-specific signals to induce cytotoxicity, created by powerful generative artificial intelligence and in vitro screening. #AdFeature with Ability Biotherapeutics https://lnkd.in/drznU2H6